Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
Gazyvaro 1,000 mg concentrate for solution for infusion., CellCept 1 g/5 ml powder for oral suspension, Gazyvaro Placebo, Myfenax 500 mg film-coated tablets
Hoffmann-La Roche
Lupus Nephritis (LN)
1 trial -
Gemcitabine
LEXICON PHARMACEUTICALS, INC.
Locally Advanced Unresectable Pancreatic Adenocarcinoma
1 trial -
Genoxal 200 mg polvo para solución inyectable y para perfusión, Fludarabina Teva 25 mg/ml concentrado para solución para perfusión o inyección EFG, AUTO1, Paracetamol MABO 500 mg comprimidos
Autolus GmbH
Relapsed or refractory B cell acute lymphoblastic leukaemia
1 trial -
Gentuximab
Changchun GeneScience Pharmaceutical Co.,
Advanced Gastric or Gastroesophageal Junction Cancer
1 trial -
Glasdegib
Jazz Pharmaceuticals Ireland Limited
Acute Myelogenous Leukemia (AML) Due to Therapy
1 trial -
Glatiramer Acetate, N-Acetylcysteine
Teva Pharma GmbH
Relapse Remitting Multiple Sclerosis
1 trial -
Gocovri (extended-release amantidine)
SUPERNUS PHARMACEUTICALS, INC.
Radiation Encephalopathy
1 trial -
Golexanolone Placebo Capsules, oral capsules, soft, GR3027 10 mg
COGNITION THERAPEUTICS INC
Primary biliary cholangitis (PBC)
1 trial -
Golimumab, Guselkumab - solution for injection in pre-filled syringe - 100 mg/mL, Placebo for Guselkumab, Golimumab and JNJ-78934804, JNJ-78934804
Janssen-Cilag International N.V.
Moderately to Severely Active Crohn's Disease
1 trial -
Guselkumab - solution for injection in pre-filled syringe - 100 mg/mL, Placebo to Guselkumab and Golimumab and JNJ-78934804, Golimumab, JNJ-78934804
Janssen-Cilag International N.V.
Moderately to Severely Active Ulcerative Colitis
1 trial -
HBI-3000
International Peace Maternity and Child Health Hospital
Atrial Fibrillation
1 trial -
HCD122
Novartis Pharmaceuticals
Non-Hodgkin's Lymphoma
1 trial -
HEC110114 tablet
Sunshine Guojian Pharmaceutical (Shanghai) Co.,
Chronic Hepatitis C
2 trials -
HEC121120 tablets
Sunshine Guojian Pharmaceutical (Shanghai) Co.,
Hepatitis B, Chronic
1 trial -
HEC169096
Sunshine Guojian Pharmaceutical (Shanghai) Co.,
Advanced Solid Tumor
1 trial -
HEC585
Sunshine Guojian Pharmaceutical (Shanghai) Co.,
Idiopathic Pulmonary Fibrosis
5 trials -
HEC585 dose A
Sunshine Guojian Pharmaceutical (Shanghai) Co.,
Progressive Fibrosing Interstitial Lung Disease (PF-ILD) / Progressive Pulmonary Fibrosis (PPF)
1 trial -
HEC96719
Sunshine Guojian Pharmaceutical (Shanghai) Co.,
Non-Alcoholic Steatohepatitis
1 trial -
HPV DNA Plasmids Therapeutic Vaccine VGX-3100
INOVIO PHARMACEUTICALS, INC.
Anal Intraepithelial Neoplasia
1 trial -
HT-001, HT-001, The corresponding placebo is formulated using the same excipients as HT-001 and is identical in color and physical appearance., HT-001
Hoth Therapeutics
Skin Toxicities Associated with Epidermal Growth Factor Receptor Inhibitors
1 trial -
HT-100
Processa Pharmaceuticals
Duchenne Muscular Dystrophy
2 trials -
HYDROCORTISONE, PREDNISOLONE ACETATE PH. EUR., ASCIMINIB HYDROCHLORIDE, CYTARABINE, DEXAMETHASONE, BLINATUMOMAB, Asciminib, METHOTREXATE, DBL methotrexate injection, VINCRISTINE SULFATE, DEXAMETHASONE SODIUM PHOSPHATE
Novartis Pharmaceuticals
relapsed or refractory BCR::ABL1-positive (Philadelphia positive, Ph+) or BCR::ABL1-like (Ph-like) acute lymphoblastic leukemia (ALL)
1 trial -
HYDROXYZINE , PARACETAMOL , IBUPROFEN , CETIRIZINE , FEXOFENADINE , mRNA-3210, DIPHENHYDRAMINE , FAMOTIDINE
Moderna Biotech Spain
Participants with Phenylketonuria
1 trial -
Hexyon suspension for injection in pre-filled syringe Diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inactivated) and Haemophilus influenzae type b conjugate vaccine (adsorbed)., MenQuadfi solution for injection Meningococcal Group A, C, W and Y conjugate vaccine, RotaTeq oral solution Rotavirus vaccine (live), Bexsero suspension for injection in pre-filled syringe Meningococcal group B Vaccine (rDNA, component, adsorbed), MenPenta SD, Prevenar 13 suspension for in
Sanofi-aventis Healthcare Pty Ltd
Meningococcal immunization
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources